47.09
Crispr Therapeutics Ag 주식(CRSP)의 최신 뉴스
Why CRISPR Therapeutics AG (CRSP) Performed Better Than the Market Today - Bitget
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - Yahoo Finance Singapore
CRISPR Therapeutics stock dips on $350M convertible debt offering - MSN
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,182 Shares - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,020 Shares - MarketBeat
Crispr Therapeutics Insider Sold Shares Worth $468,736, According to a Recent SEC Filing - marketscreener.com
CRISPR (CRSP) GC granted options, RSUs; sells shares for taxes - Stock Titan
CRISPR Therapeutics (CRSP) CEO gets major equity awards, sells shares for taxes - Stock Titan
[Form 4] CRISPR Therapeutics AG Insider Trading Activity - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) grants CMO stock options and RSUs - Stock Titan
CRISPR Therapeutics Hits Day Low of $45.88 Amid Price Pressure - Markets Mojo
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
What's going on with CRISPR Therapeutics stock today? - MSN
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore
CRSP Stock Price, Quote & Chart | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - MSN
JPMorgan Chase & Co. Has $38.46 Million Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Here is why CRISPR Therapeutics (CRSP) appears so good - MSN
CRISPR Therapeutics AG (CRSP) registers a bigger fall than the market: Important facts to note - MSN
This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough. - Barchart
Is CRISPR Therapeutics Stock a Buy Now? - The Motley Fool
Assessing CRISPR Therapeutics (CRSP) Valuation After CASGEVY Traction And US$600m Convertible Notes Raise - Sahm
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
CRISPR Therapeutics gains amid takeover speculation - MSN
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
CRISPR Therapeutics AG (CRSP) Declines Sharply Compared to Overall Market: Essential Information for Investors - Bitget
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics AG Bonds — Corporate Bond Rates - TradingView
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
CRISPR Therapeutics (CRSP) Is Down 5.1% After $550M Convertible Notes OfferingHas The Bull Case Changed? - simplywall.st
(CRSP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Piper Sandler raises CRISPR Therapeutics price target on cash raise By Investing.com - Investing.com South Africa
Volatility Watch: Is CRISPR Therapeutics AG showing insider buyingInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,349 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Insider Naimish Patel Sells 3,150 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ: CRSP) CMO vests RSUs, mandated tax sale - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) CFO covers RSU taxes with share sale and gift - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) GC sells shares for tax withholding - Stock Titan
CRISPR Therapeutics (CRSP) CEO logs RSU vesting and tax-driven share sale - Stock Titan
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
Crispr Therapeutics Completes $600 Million Convertible Notes Offering - The Globe and Mail
Goodwin Guides CRISPR Therapeutics On Pricing $550 Million Upsized Convertible Senior Notes Offering - Mondaq
Piper Sandler Raises Price Target for CRSP to $110, Reiterates O - GuruFocus
Is CRISPR Therapeutics (CRSP) the best gene-editing stock to buy now? - MSN
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler raises CRISPR Therapeutics price target on cash raise - Investing.com
CRISPR Therapeutics (NASDAQ: CRSP) sells $600M 2031 convertible notes - Stock Titan
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ark Invest Increases Holdings in CRISPR Therapeutics (CRSP) - GuruFocus
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know - MSN
Clough Capital Partners L P Makes New $1.49 Million Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics prices $550M convertible notes offering By Investing.com - Investing.com Nigeria
Is CRISPR Therapeutics (CRSP) Pricing Reflecting Gene Editing Potential After Recent Share Pullback - Yahoo Finance
CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story - Sahm
CRISPR Therapeutics shares drop after announcing convertible notes sale - MSN
자본화:
|
볼륨(24시간):